Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

bluebird bio Company Profile (NASDAQ:BLUE)

Consensus Ratings for bluebird bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $41.30 (20.06% upside)

Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
DateFirmActionRatingPrice TargetDetailsShare
6/18/2014JPMorgan Chase & Co.Reiterated RatingOverweight$44.00 -> $53.00ViewTweet This Rating  Share This Rating on StockTwits
6/16/2014WedbushBoost Price Target$51.00ViewTweet This Rating  Share This Rating on StockTwits
6/13/2014Piper JaffrayInitiated CoverageOverweightViewTweet This Rating  Share This Rating on StockTwits
5/14/2014ZacksUpgradeUnderperform -> Neutral$19.90ViewTweet This Rating  Share This Rating on StockTwits
3/10/2014ZacksDowngradeNeutral -> Underperform$24.70ViewTweet This Rating  Share This Rating on StockTwits
7/30/2013Cowen and CompanyInitiated CoverageOutperform$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013WedbushInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
7/15/2013JPMorgan Chase & Co.Initiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
7/15/2013Canaccord GenuityInitiated CoverageBuy$45.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013JPMorgan Chase & Co.Initiated CoverageOverweight$44.00ViewTweet This Rating  Share This Rating on StockTwits
7/15/2013Bank of AmericaInitiated CoverageBuy$42.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 7/31/2012 forward)